0000899243-21-009499.txt : 20210303
0000899243-21-009499.hdr.sgml : 20210303
20210303183921
ACCESSION NUMBER: 0000899243-21-009499
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210301
FILED AS OF DATE: 20210303
DATE AS OF CHANGE: 20210303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MAHAFFY PATRICK J
CENTRAL INDEX KEY: 0001266569
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35347
FILM NUMBER: 21711308
MAIL ADDRESS:
STREET 1: C/O CLOVIS ONCOLOGY, INC.
STREET 2: 5500 FLATIRON PARKWAY, SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clovis Oncology, Inc.
CENTRAL INDEX KEY: 0001466301
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 900475355
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: (303) 625-5000
MAIL ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-01
0
0001466301
Clovis Oncology, Inc.
CLVS
0001266569
MAHAFFY PATRICK J
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100
BOULDER
CO
80301
1
1
0
0
See Remarks
Stock Option (right to buy)
6.23
2021-03-01
4
A
0
220000
0.00
A
2031-03-01
Common Stock
220000
220000
D
Stock Option (right to buy)
6.23
2021-03-01
4
A
0
80000
0.00
A
2031-03-01
Common Stock
80000
80000
D
Stock Option (right to buy)
6.23
2021-03-01
4
A
0
40000
0.00
A
2031-03-01
Common Stock
40000
40000
D
Stock Option (right to buy)
6.23
2021-03-01
4
A
0
40000
0.00
A
2031-03-01
Common Stock
40000
40000
D
The option shall vest as to 25% of the shares on March 1, 2022, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.
The option shall vest in the event Product Revenues for the Company's fiscal year ending December 31, 2021 meet or exceed its corresponding budgeted amount in the Company's budget as approved by the Board on December 8, 2020.
The option shall vest upon the selection of an alpha-emitter agent for use in the study of the Company's product candidate FAP-2286 on or before December 31, 2021.
The option shall vest upon the enrollment of three dose cohorts in the Company's LuMIERE study on or before December 31, 2021.
President and Chief Executive Officer
/s/ Patrick J. Mahaffy
2021-03-03